Related Experiment Video
Updated: Aug 22, 2025
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches
Katarzyna A Roszkowska1, Aleksandra Piecuch1, Maria Sady1
1Center for Translational Medicine, Warsaw University of Life Sciences, 100 Nowoursynowska St., 02-797 Warsaw, Poland.
Abstract:
Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients' comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p53 reactivation or the destabilization of mutant p53 are being investigated. Several of them, APR-246, COTI-2, SAHA, and PEITC, were approved for clinical trials. This review focuses on these novel therapeutic opportunities, their mechanisms of action, and their significance for potential medical application.
Insights
Targeting mutant TP53 offers new hope for cancer patients. Reactivating or destabilizing mutant p53 with compounds like APR-246 shows promise in clinical trials for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutant TP53 is linked to poor cancer prognosis, including metastasis and chemoresistance.
- Personalized treatments are crucial for improving cancer patient survival and comfort.
- Developing novel therapies targeting mutant TP53 is an active area of research.
Purpose of the Study:
- To review novel therapeutic strategies targeting mutant TP53.
- To discuss the mechanisms of action for these compounds.
- To evaluate their potential for clinical application in oncology.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of compounds targeting mutant TP53 reactivation or destabilization.
- Focus on compounds that have entered clinical trials.
Main Results:
- Several compounds, including APR-246, COTI-2, SAHA, and PEITC, are under investigation.
- These agents demonstrate potential in reactivating or destabilizing mutant p53.
- Clinical trials are evaluating the efficacy and safety of these novel therapies.
Conclusions:
- Targeting mutant TP53 represents a promising avenue for personalized cancer therapy.
- Compounds like APR-246, COTI-2, SAHA, and PEITC offer new therapeutic opportunities.
- Further research and clinical trials are essential to realize the medical significance of these agents.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:38Mitogens and the Cell Cycle
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...